Viracta Therapeutics, Inc. (VIRX)
USD 0.02
(14.44%)
USD 0.02
(14.44%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -46.86 Million USD | 0.77% |
| 2022 | -48.41 Million USD | -180.71% |
| 2021 | -114.09 Million USD | 433.95% |
| 2020 | -18.76 Million USD | -55.69% |
| 2019 | -22.81 Million USD | 53.09% |
| 2018 | -25.45 Million USD | 25.31% |
| 2017 | -34.05 Million USD | 5.59% |
| 2016 | -36.29 Million USD | 7.2% |
| 2015 | -35.71 Million USD | 4.8% |
| 2014 | -41.25 Million USD | -30.3% |
| 2013 | -31.66 Million USD | 24.73% |
| 2012 | -42.06 Million USD | -112.61% |
| 2011 | -20.08 Million USD | 19.04% |
| 2010 | -24.43 Million USD | 38.73% |
| 2009 | -39.88 Million USD | -11.06% |
| 2008 | -35.91 Million USD | 2.48% |
| 2007 | -36.82 Million USD | -26.2% |
| 2006 | -29.17 Million USD | -16.05% |
| 2005 | -25.14 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -13.76 Million USD | 35.61% |
| 2024 Q2 | -9.49 Million USD | -10.57% |
| 2023 Q3 | -12.47 Million USD | -0.2% |
| 2023 Q1 | -12.29 Million USD | -6.26% |
| 2023 Q2 | -12.45 Million USD | -1.24% |
| 2023 FY | - USD | 0.77% |
| 2023 Q4 | -13.43 Million USD | -7.71% |
| 2022 Q2 | -10.4 Million USD | -0.32% |
| 2022 FY | - USD | -180.71% |
| 2022 Q1 | -10.36 Million USD | 8.39% |
| 2022 Q4 | -11.57 Million USD | 34.09% |
| 2022 Q3 | -17.55 Million USD | -68.82% |
| 2021 Q2 | -9.25 Million USD | -272.39% |
| 2021 Q1 | 5.36 Million USD | 187.74% |
| 2021 Q4 | -11.31 Million USD | -5.41% |
| 2021 Q3 | -10.73 Million USD | -16.03% |
| 2021 FY | - USD | 433.95% |
| 2020 Q4 | -6.11 Million USD | -52.87% |
| 2020 Q1 | -4.41 Million USD | 16.57% |
| 2020 FY | - USD | -55.69% |
| 2020 Q2 | -4.23 Million USD | 4.1% |
| 2020 Q3 | -4 Million USD | 5.48% |
| 2019 Q2 | -6.12 Million USD | -9.49% |
| 2019 Q3 | -5.86 Million USD | 4.23% |
| 2019 Q4 | -5.29 Million USD | 9.83% |
| 2019 FY | - USD | 53.09% |
| 2019 Q1 | -5.59 Million USD | 1.79% |
| 2018 Q3 | -6.21 Million USD | 5.17% |
| 2018 FY | - USD | 25.31% |
| 2018 Q2 | -6.55 Million USD | 6.28% |
| 2018 Q1 | -6.99 Million USD | -10.23% |
| 2018 Q4 | -5.69 Million USD | 8.26% |
| 2017 Q4 | -6.34 Million USD | 35.74% |
| 2017 Q3 | -9.86 Million USD | -16.15% |
| 2017 FY | - USD | 5.59% |
| 2017 Q2 | -8.49 Million USD | 9.11% |
| 2017 Q1 | -9.34 Million USD | -15.98% |
| 2016 Q4 | -8.06 Million USD | 4.94% |
| 2016 Q3 | -8.47 Million USD | 14.93% |
| 2016 FY | - USD | 7.2% |
| 2016 Q2 | -9.96 Million USD | -1.86% |
| 2016 Q1 | -9.78 Million USD | 13.72% |
| 2015 FY | - USD | 4.8% |
| 2015 Q3 | -6.78 Million USD | 22.04% |
| 2015 Q4 | -11.34 Million USD | -67.12% |
| 2015 Q2 | -8.7 Million USD | 1.95% |
| 2015 Q1 | -8.87 Million USD | -786.91% |
| 2014 Q2 | -11.3 Million USD | 19.37% |
| 2014 FY | - USD | -30.3% |
| 2014 Q1 | -14.02 Million USD | -114.06% |
| 2014 Q4 | -1 Million USD | 93.29% |
| 2014 Q3 | -14.92 Million USD | -32.04% |
| 2013 Q4 | -6.55 Million USD | 5.18% |
| 2013 Q3 | -6.9 Million USD | 6.86% |
| 2013 FY | - USD | 24.73% |
| 2013 Q2 | -7.41 Million USD | 31.23% |
| 2013 Q1 | -10.78 Million USD | -236.43% |
| 2012 Q3 | -17 Million USD | -105.97% |
| 2012 FY | - USD | -112.61% |
| 2012 Q4 | -3.2 Million USD | 81.14% |
| 2012 Q1 | -13.6 Million USD | -55.78% |
| 2012 Q2 | -8.25 Million USD | 39.31% |
| 2011 Q3 | -5 Million USD | 39.05% |
| 2011 Q1 | 1.86 Million USD | 118.55% |
| 2011 Q2 | -8.21 Million USD | -540.79% |
| 2011 FY | - USD | 19.04% |
| 2011 Q4 | -8.73 Million USD | -74.45% |
| 2010 Q2 | -4.73 Million USD | -3.03% |
| 2010 FY | - USD | 38.73% |
| 2010 Q4 | -10.04 Million USD | -98.67% |
| 2010 Q3 | -5.05 Million USD | -6.67% |
| 2010 Q1 | -4.59 Million USD | -15.66% |
| 2009 FY | - USD | -11.06% |
| 2009 Q3 | -4.87 Million USD | 78.62% |
| 2009 Q2 | -22.78 Million USD | -176.09% |
| 2009 Q1 | -8.25 Million USD | -21.07% |
| 2009 Q4 | -3.97 Million USD | 18.35% |
| 2008 Q1 | -9.18 Million USD | -10.1% |
| 2008 Q3 | -6.93 Million USD | 47.19% |
| 2008 Q4 | -6.81 Million USD | 1.77% |
| 2008 Q2 | -13.13 Million USD | -42.99% |
| 2008 FY | - USD | 2.48% |
| 2007 Q3 | -10.4 Million USD | -11.38% |
| 2007 Q2 | -9.34 Million USD | -4.48% |
| 2007 Q1 | -8.94 Million USD | -3.7% |
| 2007 Q4 | -8.34 Million USD | 19.79% |
| 2007 FY | - USD | -26.2% |
| 2006 Q2 | -4.1 Million USD | 52.22% |
| 2006 Q4 | -8.62 Million USD | -3.43% |
| 2006 FY | - USD | -16.05% |
| 2006 Q1 | -8.59 Million USD | -74.99% |
| 2006 Q3 | -8.33 Million USD | -103.09% |
| 2005 Q3 | -5.59 Billion USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | -4.9 Million USD | 99.91% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -10376.825% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -58.822% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 58.912% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -197.329% |
| Better Therapeutics, Inc. | -38.26 Million USD | -22.477% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -22.467% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -161.995% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -38.92% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -40.419% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 55.934% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -5030.091% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -44.271% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -0.364% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -724.491% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -187.476% |
| Molecular Templates, Inc. | 1.43 Million USD | 3377.063% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -237.742% |
| NexImmune, Inc. | -28.16 Million USD | -66.369% |
| Orgenesis Inc. | -60.71 Million USD | 22.82% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 8.64% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -63730.773% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -190.252% |
| Scopus BioPharma Inc. | -11.71 Million USD | -300.08% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 91.321% |
| Statera Biopharma, Inc. | 38.93 Million USD | 220.36% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -580.738% |
| Trevena, Inc. | -35.28 Million USD | -32.799% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -83506.002% |
| Vaccinex, Inc. | -19.74 Million USD | -137.3% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -4375.93% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -545.214% |